Aidan K Curran
Overview
Explore the profile of Aidan K Curran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodie S, Curran A, Gonzalez-Nelson A, Perry J, Manning D, Wasilewski M
Headache
. 2024 May;
64(6):643-651.
PMID: 38717120
Background: Intravenous dihydroergotamine (DHE) has well-established efficacy for the acute treatment of migraine, but its use is limited by the need for in-hospital administration and the nausea/vomiting associated with a...
2.
Bergagnini-Kolev M, Kane K, Templeton I, Curran A
AAPS J
. 2023 Jun;
25(4):62.
PMID: 37344751
Itraconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), associated with numerous drug-drug interactions (DDI). PUR1900, a dry powder formulation of itraconazole for oral inhalation, results in high lung...
3.
Edwards D, Hickey A, Batycky R, Griel L, Lipp M, Dehaan W, et al.
QRB Discov
. 2021 Jun;
1:e5.
PMID: 34192261
We propose the nasal administration of calcium-enriched physiological salts as a new hygienic intervention with possible therapeutic application as a response to the rapid and tenacious spread of COVID-19. We...
4.
Curran A, Hava D
Antibiotics (Basel)
. 2021 Apr;
10(4).
PMID: 33800658
spp. are spore forming molds; a subset of which are clinically relevant to humans and can cause significant morbidity and mortality. causes chronic infection in patients with chronic lung disease...
5.
Hava D, Tan L, Johnson P, Curran A, Perry J, Kramer S, et al.
Br J Clin Pharmacol
. 2019 Nov;
86(4):723-733.
PMID: 31696544
Aims: Oral itraconazole has variable pharmacokinetics and risks of adverse events associated with high plasma exposure. An inhalation formulation of itraconazole (PUR1900) is being developed to treat allergic bronchopulmonary aspergillosis,...
6.
Ingram-Ross J, Curran A, Miyamoto M, Sheehan J, Thomas G, Verbeeck J, et al.
J Pharmacol Toxicol Methods
. 2012 Apr;
66(2):114-24.
PMID: 22521338
Introduction: This study was designed to provide a comprehensive nonclinical respiratory safety pharmacology assessment using respiratory inductance plethysmography (RIP) concomitant with a standard cardiovascular (CV) safety assessment in non-human primates...
7.
Chapman R, Curran A, House A, Richard J, Salisbury B, Hunter J, et al.
Pulm Pharmacol Ther
. 2010 Oct;
24(1):67-73.
PMID: 20937404
Mometasone furoate (MF)/formoterol fumarate (F) combination is a new inhaIed corticosteroid/long-acting β₂-adrenergic agonist (ICS/LABA). The purpose of this study was to evaluate the effects of different dose combinations of MF/F...
8.
Dragomir A, Akay Y, Curran A, Akay M
J Neuroeng Rehabil
. 2008 Jun;
5:17.
PMID: 18570656
Background: The laryngeal chemoreflex exists in infants as a primary sensory mechanism for defending the airway from the aspiration of liquids. Previous studies have hypothesized that prolonged apnea associated with...
9.
Curran A, Skeans S, Landers D, Chapman R
J Asthma
. 2008 Jun;
45(5):377-81.
PMID: 18569230
The proximal and distal portions of the lungs may respond differently to antigen challenge and bronchodilator treatment. This difference may contribute to differences in actual and perceived efficacy of therapies....
10.
Dragomir A, Akay Y, Curran A, Akay M
J Neural Eng
. 2008 May;
5(2):254-61.
PMID: 18506077
Since sleep is known to influence respiratory activity we studied whether the sleep state would affect the complexity value of the respiratory network output. Specifically, we tested the hypothesis that...